biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
biote Corp.NASDAQ: BTMD
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow declines year over year
Q1 FY2026 investing cash flow of $1.17M (cash outflow) fell 36.8% year over year, behind the -27.0% change in trailing-twelve-month investing cash flow. Sequentially, it fell 50.6% from the prior quarter. Over 3 fiscal years it compounded at +55.1% a year.
Context
- Investing cash flow amounted to 3.6% of revenue in FY2025, down 6.0 pp from a year earlier.
- Investing cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -36.8% toward the trailing-twelve-month pace of -27.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (6.86M) USD
- Year-over-year change
- +63.5%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.86M) | +63.5% |
| FY2024 | 2024-12-31 | (18.8M) | -592.9% |
| FY2023 | 2023-12-31 | (2.71M) | -47.6% |
| FY2022 | 2022-12-31 | (1.84M) | +51.7% |
| FY2021 | 2021-12-31 | (3.81M) | — |
Investing Cash Flow vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 investing cash flow of $6.18M is the 5th largest of the 11 companies compared; the peer median is $4K.
- Its year-over-year change of -27.0% is the 4th highest of 9, against a peer median of -43.2%.
- Investing cash flow amounts to 3.3% of revenue for BTMD, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $311.81M | -692.2% | -19.7% | — | |
| LTM Mar 2026 | $91.44M | +6.4% | +50.6% | — | |
| LTM Mar 2026 | $16.73M | -71.5% | -49.6% | — | |
| LTM Mar 2026 | $6.33M | +1195.4% | — | 11.2% | |
| LTM Mar 2026 | $6.18M | -27.0% | +55.1% | 3.3% | |
| LTM Mar 2026 | $4.63M | +58.7% | — | 13.7% | |
| LTM Mar 2026 | $3.31M | -31.8% | -62.3% | 2.8% | |
| LTM Mar 2026 | $319K | -54.6% | -63.7% | 6.2% | |
| LTM Mar 2026 | $8K | -100.0% | — | 0.7% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding BTMD) | $4K | -43.2% | -49.6% | 4.5% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 32.62M | 1.32M | 3.32M | 46K | 27.05M |
| Depreciation & Amortization | 1.4M | 2.2M | 2.99M | 3.57M | 3.67M |
| Deferred Income Tax | 0 | (743K) | 721K | (2.9M) | 3.98M |
| Stock-Based Compensation | 0 | 82.18M | 9.06M | 8.74M | 8.92M |
| Change in Working Capital | (1.46M) | (35.81M) | (8.93M) | 9.93M | (8.25M) |
| Accounts Receivables | (752K) | (1.56M) | (505K) | (2.27M) | (958K) |
| Inventory | (5.76M) | (1.71M) | (6.1M) | 3.71M | (6.24M) |
| Accounts Payables | 1.61M | 416K | (165K) | 1.55M | 1.01M |
| Other Working Capital | 3.45M | (32.96M) | (2.16M) | 6.94M | (2.06M) |
| Other Non-Cash Items | 1.16M | (58.3M) | 19.72M | 25.85M | (165K) |
| Operating Cash Flow | 33.72M | (9.16M) | 26.88M | 45.24M | 35.19M |
| Capital Expenditures | (3.81M) | (1.84M) | (2.71M) | (6.43M) | (5.02M) |
| Acquisitions (Net) | 0 | 0 | 0 | (11.84M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (2.36M) | (1.51M) | (2.35M) | (526K) | (1.85M) |
| Investing Cash Flow | (3.81M) | (1.84M) | (2.71M) | (18.8M) | (6.86M) |
| Debt Repayment | (5M) | 84.38M | (6.25M) | (6.25M) | (1.25M) |
| Common Stock Issued | 0 | 442K | 144K | 282K | 368K |
| Common Stock Repurchased | 0 | (424K) | 0 | (5.6M) | (3.37M) |
| Dividends Paid | (11.4M) | (12.89M) | (8.69M) | (4.74M) | (1.73M) |
| Other Financing Activities | (3.94M) | (8.05M) | 420K | (59.77M) | (37.58M) |
| Financing Cash Flow | (20.34M) | 63.46M | (14.38M) | (76.08M) | (43.56M) |
| Effect of Forex Changes | (12K) | 0 | (19K) | (22K) | 6K |
| Net Change in Cash | 9.56M | 52.47M | 9.77M | (49.66M) | (15.22M) |
| Free Cash Flow | 29.91M | (11M) | 24.17M | 38.81M | 30.18M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.